Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07389941
PHASE4
Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
Sponsor: University of Luebeck
View on ClinicalTrials.gov
Summary
To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.
Official title: Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2026-10
Completion Date
2029-04
Last Updated
2026-02-11
Healthy Volunteers
No
Conditions
Interventions
DRUG
Semaglutide (SEMA)
Catheter ablation for AF plus semaglutide (up to 2.4 mg weekly)